| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd. Gold
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Gevokizumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Gevokizumab
CAS:1129435-60-4
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:IMMunoglobulin G2
CAS:1129435-60-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10801
|
|
| | IMMunoglobulin G2 Basic information |
| Product Name: | IMMunoglobulin G2 | | Synonyms: | IMMunoglobulin G2;Research Grade Gevokizumab(DHB95602);Gevokizumab (anti-IL-1b);Research Grade Gevokizumab;Gevokizumab | | CAS: | 1129435-60-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![IMMunoglobulin G2 Structure]() |
| | IMMunoglobulin G2 Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | IMMunoglobulin G2 Usage And Synthesis |
| Uses | Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2]. | | in vivo | Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2].
| Animal Model: | Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2] | | Dosage: | 1, 10 and 50 mg/kg | | Administration: | Intravenous injection; once daily for 3 days | | Result: | Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg. |
| | References | [1] Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. DOI:10.1124/jpet.113.205443
[2] Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85. DOI:10.1016/j.atherosclerosis.2014.07.012 |
| | IMMunoglobulin G2 Preparation Products And Raw materials |
|